Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.32 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.31 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.31 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.31 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL630191 | 0.73 | CHRNA7 (0.36) | CYP19A1CYP11B1CYP11B2HDAC6CHRNA7 | |
| SCHEMBL630163 | 0.69 | PTPN1 (0.43) | CYP19A1CYP11B1CYP11B2HDAC6CHRNA7 | |
| SCHEMBL630295 | 0.68 | HDAC6 (0.38) | CYP19A1CYP11B1CYP11B2HDAC6CHRNA7 | |
| SCHEMBL3579427 | 0.68 | CHRNA7 (0.33) | CHRNA7PDE4BAGTR2 | |
| SCHEMBL25339951 | 0.62 | PTPN2 (0.47) | — | |
| SCHEMBL18983590 | 0.61 | HRH3 (0.59) | — | |
| SCHEMBL5892874 | 0.58 | GSK3A (0.49) | CRBN | |
| SCHEMBL629810 | 0.58 | CHRNA7 (0.39) | CYP19A1CYP11B1CYP11B2HDAC6CHRNA7 | |
| SCHEMBL8536091 | 0.58 | LMNA (0.50) | — | |
| SCHEMBL21054283 | 0.57 | MAOB (0.43) | CHRNA7PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700633-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| US-20080262050-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262050-A1 | Organic Compounds | PTPRS, PTPRO, PTPRC | CYP19A1 1316/4885CYP11B1 1495/4885CYP11B2 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.